Drugs that contain Rimegepant Sulfate
1. List of Nurtec Odt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8314117 | BIOHAVEN IRELAND | CGRP receptor antagonists |
Feb, 2031
(7 years from now) | |
| US8759372 | BIOHAVEN IRELAND | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | BIOHAVEN IRELAND | Rimegepant for CGRP related disorders |
Mar, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 27, 2025 |
| New Indication (I) | May 27, 2024 |
NCE-1 date: 2024-02-28
Market Authorisation Date: 27 February, 2020
Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT family patents
18
United States
6
Korea, Republic of
6
Japan
5
European Union
4
Canada
3
Australia
3
EA
3
Israel
3
Croatia
3
Denmark
3
Spain
3
Portugal
3
Poland
3
Slovenia
3
Mexico
3
RS
3
China
3
Brazil
3
Hungary
3
Lithuania
2
Cyprus
2
Singapore
2
Norway
2
Hong Kong
2
Argentina
1
Colombia
1
Netherlands
1
New Zealand
1
Tunisia
1
Peru
1
Chile
1
Philippines
1
San Marino
1
South Africa
1
Taiwan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic